PharmaCorp Announces Fourth Quarter and Fiscal Year 2025 Financial Results

About this update from Pharmacorp Rx Inc.

[{"type":"text","content":"PharmaCorp Announces Fourth Quarter and Fiscal Year 2025 Financial Results\nFourth quarter 2025 revenue up 75% compared to the fourth quarter 2024Fourth quarter 2025 gross profit increased 78% compared to the fourth quarter 2025Fourth quarter same-store sales up 6% and same-store prescription sales up 3.8 %, supplementary financial measures, both compared to fourth quarter 2025 SASKATOON, Saskatchewan, April 29, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) a Canadian pharmacy acquisition and ownership platform for pharmacist-led community pharmacy ownership, today reported its financial results for fourth quarter and year ended December 31, 2025. “Our financial results reflect our steady progress in scaling the business through disciplined M&A, the successful integration of recently acquired stores, and the operational excellence of our pharmacies,” said Alan Simpson, Executive Chairman of PharmaCorp. “Looking ahead, the ongoing interest from independent pharmacy owners considering their succession options continues to fuel the expansion of our unique pipeline of M&A opportunities across Canada. We remain confident in our ability to further scale our business through accretive transactions in fiscal 2026 as we work towards building a national platform.” Fourth Quarter 2025 and Fiscal Year 2025 Financial Highlights Fourth quarter 2025 revenue of $7.7 million compared to $4.4 million in the fourth quarter of 2024, representing an increase of 75 %. Fiscal year 2025 revenue of $20.9 million compared to $5.8 million in 2024.Fourth quarter 2025 gross profit of $2.9 million compared to $1.7 million in the fourth quarter of 2024 with margins of 39% and 38% respectively. Fiscal year 2025 gross profit of $8.3 million compared to $2.2 million in 2024.Fiscal year 2025 Adjusted EBITDA, a Non-IFRS Financial Measure, of $3.5 million compared to $0.85 million in 2024.Revenues, gross profit and Adjusted EBITDA were higher year-over-year for the quarterly and annual periods due to increases in prescription volumes and front-of-store sales and owning more pharmacies in the fourth quarter of 2025 and fiscal 2025 versus the prior-year periods.Fourth quarter same-store sales, a supplementary financial measure, increased 6% compared to ...

More updates from Pharmacorp Rx Inc.